SAShanta Alli

Shanta Alli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shanta Alli has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy

    by Tae Gun Kang, Xin Lan, Tian Mi, Hongfeng Chen, Shanta Alli, Song-Eun Lim, Sheetal Bhatara, Anoop Babu Vasandan, Grace Ward, Sofia Bentivegna, et al.

    Epigenetic reinforcement of T cell exhaustion is known to be a major barrier limiting T cell responses during immunotherapy. However, the core epigenetic regulators restricting antitumor immunity during prolonged antigen exposure are not clear. We investigated three commonly mutated epigenetic regulators that promote clonal hematopoiesis to determine whether they affect T cell stemness and response to checkpoint blockade immunotherapy. CD8 T cells lacking Dnmt3a, Tet2, or Asxl1 preserved a progenitor-exhausted (Tpex) population for more than 1 year during chronic antigen exposure without undergoing malignant transformation. Asxl1 controlled the self-renewal capacity of T cells and reduced CD8 T cell differentiation through H2AK119 ubiquitination and epigenetic modification of the polycomb group–repressive deubiquitinase pathway. Asxl1-deficient T cells synergized with anti–PD-L1 immunotherapy to improve tumor control in experimental models and conferred a survival advantage to mutated T cells from treated patients.


  • Antigen cross-presentation in young tumor-bearing hosts promotes CD8 + T cell terminal differentiation

    by Ardiana Moustaki, Jeremy Chase Crawford, Shanta Alli, Yiping Fan, Shannon Boi, Anthony E. Zamora, Natalie M. N. McDonald, Gang Wu, Joy Nakitandwe, Scott Newman, et al.

    The immune system undergoes a progressive functional remodeling with age. Understanding how age bias shapes antitumor immunity is essential in designing effective immunotherapies, especially for pediatric patients. Here, we explore antitumor CD8 + T cell responses generated in young (prepubescent) and adult (presenescent) mice. Using an MHCI-deficient tumor model, we observed that tumor-reactive CD8 + T cells expanded in young tumor-bearing (TB) mice acquired a terminally differentiated phenotype characterized by overexpression of inhibitory receptors and the transcription factor Tox1. Furthermore, tumor-infiltrating CD8 + T cells from young tumors yielded a poor cytokine response compared with CD8 + T cells infiltrating adult tumors. Young migratory dendritic cells (migDCs) from the draining lymph nodes (dLNs), and mononuclear phagocytic cells (MPCs) infiltrating young tumors, were more competent in capturing and cross-presenting tumor antigen, leading to enhanced priming of CD8 + T cells in dLNs and their subsequent terminal differentiation in the tumors. Single-cell transcriptional profiling of tumor-infiltrating MPCs demonstrated that young MPCs are polarized toward an inflammatory, effector phenotype. Consistent with our observations in young versus adult TB mice, analysis of immune infiltrates from pediatric solid tumors showed a correlation between tumor-infiltrating CD8 + T cells with an exhaustion phenotype and the frequency of PD-L1–expressing monocytes/macrophages. Collectively, these data indicate that a young tissue microenvironment contributes to the generation of an immune response skewed toward a less pliable terminal effector state, thus narrowing the window for immunotherapeutic interventions.


  • Top Cited Papers

    Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

    by Brooke Prinzing, Caitlin C. Zebley, Christopher T. Petersen, Yiping Fan, Alejandro Allo Anido, Zhongzhen Yi, Phuong Nguyen, Haley Houke, Matthew Bell, Dalia Haydar, et al.

    DNMT3A deletion preserves CAR T cell functionality during prolonged stimulation.


  • Open Access

    CD19-CAR T Cells Develop Exhaustion Epigenetic Programs during a Clinical Response

    by Caitlin C. Zebley, Charmaine Brown, Tian Mi, Yiping Fan, Shanta Alli, Shannon Boi, Giovanni Galletti, Enrico Lugli, Deanna Langfitt, Jean-Yves Metais, et al.

    Background: CD19-CAR T-cell therapy has emerged as a curative approach for patients with relapsed/refractory B-cell malignancies, including lymphoma and acute lymphoblastic leukemia (ALL). However, many patients develop recurrent disease after initial responses. Therapeutic failure is most likely due to T cell extrinsic and intrinsic mechanisms. While CD19-negative relapse has emerged as a major extrinsic mechanism, T cell intrinsic mechanisms remain elusive. T-cell exhaustion is driven by epigenetic programs, however epigenetic changes in CAR T cells pre and post infusion have not been determined longitudinally. Thus, the goal of this study was to determine the epigenetic landscape of CD19-CAR T cells pre and post infusion as an initial step to elucidate intrinsic mechanisms that limit CAR T-cell effector functions in humans. Methods/Results: A longitudinal analysis of CD8+ CD19-CAR T cell epigenetic changes was performed by whole-genome DNA methylation profiling of CAR T cells during manufacturing and from peripheral blood mononuclear cells (PBMCs) of infused patients. DNA methylation profiling was performed on samples from 15 patients enrolled on our institutional, autologous CD19-CAR T cell therapy study (NCT03573700). CAR T cell expansion and persistence was determined by measuring vector copy numbers in the PBMCs of treated patients. B cell aplasia was tracked by monitoring B cell reconstitution as an additional measure of CD19-CAR T cell function. We had previously established novel exhaustion DNA methylation datasets that delineate between progenitor and fully exhausted T cells. These datasets served as a guide for stratifying our post-infusion CAR T cells along the exhaustion developmental trajectory. Lastly, publicly available single-cell transcriptional profiles of CD19-CAR T cells from patients were mined to validate expression of the transitory exhaustion signature. Our data show that CD19-CAR T cells lose repressive DNA methylation at effector loci (e.g. PRF1, TBET) while gaining methylation at genes (e.g. LEF1, TCF7) associated with memory potential. We confirmed that these epigenetic changes are coupled to endogenous human T cell effector and memory differentiation by cross-referencing our epigenetic data with publicly available transcriptional profiles for antigen-specific effector and long-lived memory CD8 T cells from individuals vaccinated for yellow fever. Furthermore, we show that CAR T cells were unable to mount an in vivo recall response after recovery of antigen-positive B cells or disease relapse. This observation, coupled to the fact that these patients' CAR T cells developed exhaustion-associated DNA methylation programs, further supports the broader conclusion that CAR T cells acquire stable epigenetic exhaustion programs that limit their protective capacity. Conclusion: Our data demonstrate for the first time that CAR T cell expansion during a clinical response is coupled to progressive restriction of gene regulatory programs that control T cell fate potential. Furthermore, we show that CD19-CAR T cells undergo exhaustion epigenetic programs that are coupled to an inability to mount a recall response in the presence of antigen-positive normal and malignant B cells. This work lays the foundation for future efforts aimed at improving the efficacy of cellular therapy by reversing epigenetic programs that are coupled to CAR T-cell exhaustion.

  • Abstract LB-074: Antigen-cross presentation promotes development of terminally differentiated CD8 T cells in young individuals

    by Ardiana Moustaki, Jeremy Chase Crawford, Shanta Alli, Anthony Zamora, Yiping Fan, Shannon Boi, Natalie M. McDonald, Paul G. Thomas, Alberto S. Pappo, Michael A. Dyer, et al.

    Recent advances in T cell-based immunotherapies have revolutionized treatment strategies for several types of cancers; however, approaches that rely on endogenous T cell responses have experienced limited success in pediatric populations, a pattern primarily attributed to the relatively low mutational burden characteristic of pediatric tumors. Here, we report our analysis of CD8 T cells isolated from a diverse set of pediatric solid tumors, documenting an enrichment of CD8 T cells with an antigen-experienced phenotype (i.e., high PD1 expression). The limited ability of immune checkpoint blockade therapy (ICBT) to trigger anti-tumor responses in pediatric populations, despite the presence of activated CD8 T cells in these tumors prompted us to explore alternative mechanisms restricting the endogenous T cell response. Using a novel, transplantable mouse tumor model that expresses a well-characterized epitope coupled to a mCherry marker, we identified antigen cross-presentation by tumor-infiltrating myeloid cells as a key mediator of CD8 T cell effector function in tumors. Specifically, we show that tumor microenvironment (TME)-mediated suppression of CD8 T cell polyfunctionality occurs even in the absence of direct antigen-presentation by tumor cells, suggesting that antigen cross-presentation is sufficient to enforce this dysfunctional state. Strikingly, age-related changes in the TME had a significant impact on the differentiation of tumor-specific CD8 T cells. Cross-presentation of tumor antigens in the young animals skewed the effector differentiation of tumor-specific CD8 T cells toward a TCF7lowGzmBhi terminally differentiated state. Profiling of tumor-infiltrating antigen-presenting cells by scRNAseq revealed the differential polarization of the myeloid compartment towards M1 and M2 phenotypes between the young and adult tumors, respectively. Consistent with our mouse findings, analysis of immune infiltrates from human pediatric solid tumors revealed a strong correlation between the expression of PDL1 on myeloid cells and enrichment of tumor-associated CD8 T cells with an exhaustion phenotype (PD1hiTim3+). Collectively, these data indicate that the “young” microenvironment of an actively developing tissue/individual contributes to the generation of an immune response skewed towards a terminally differentiated state with limited plasticity, thus narrowing the window for immunotherapeutic interventions. Citation Format: Ardiana Moustaki, Jeremy Chase Crawford, Shanta Alli, Anthony Zamora, Yiping Fan, Shannon Boi, Natalie M. McDonald, Paul G. Thomas, Alberto S. Pappo, Michael A. Dyer, Elizabeth Stewart, Sara Federico, Ben Youngblood. Antigen-cross presentation promotes development of terminally differentiated CD8 T cells in young individuals [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr LB-074.

  • Open Access

    Antigen-cross presentation promotes development of terminally differentiated CD8 T cells in young individuals

    by Ardiana Moustaki, Jeremy Chase Crawford, Shanta Alli, Anthony E Zamora, Yiping Fan, Shannon Boi, Natalie M N McDonald, Paul Glyndwr Thomas, Alberto Pappo, Michael Dyer, et al.

    Cancer immunotherapeutic approaches that rely on endogenous T cell responses have shown limited success in children, a pattern attributed to the low mutational burden of pediatric tumors. Here, we report that CD8 T cells isolated from a diverse set of pediatric solid tumors are enriched for an antigen-experienced phenotype. The limited ability of immune checkpoint blockade therapy (ICBT) to trigger anti-tumor responses in children, despite the presence of activated CD8 T cells, prompted us to explore alternative underlying mechanisms restricting anti-tumor responses. Using a novel mouse tumor model that expresses a well-characterized epitope coupled to an mCherry marker, we identified antigen cross-presentation by tumor infiltrating myeloid cells as a key regulator of CD8 T cell effector function in tumors. Strikingly, age-related changes in the TME resulted in a skewing of the CD8 T cell effector fate toward a terminally differentiated state in young tumor-bearing mice. Profiling of tumor infiltrating antigen presenting cells by scRNAseq revealed a proinflammatory M1 macrophage polarization in young tumors but a predominant M2 “wound healing” response in adult tumors. Consistent with our mouse findings, analysis of immune infiltrates from human pediatric solid tumors revealed a strong correlation between the expression of PDL1 on myeloid cells and enrichment of tumor-associated CD8 T cells with an exhaustion phenotype. Collectively, these data indicate that the “young” microenvironment of an actively developing tissue/individual contributes to the generation of an immune response skewed towards a terminally differentiated state with limited plasticity, thus narrowing the window for immunotherapeutic interventions.